SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
294 39 0 TRIL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
294Trillium Therapeutics stock jumps 192% after acquisition by Pfizer for $2.3B seJulius Wong18/23/2021
293AFM13/pembro more data ashpublications.orgsemi_infinite -11/19/2020
292>> AFM26 cd16a partnership disclosed........ Roche doing the preclinical..scaram(o)uche-5/20/2020
291AFM26 cd16a partnership disclosed because of upcoming meeting. Roche doing the semi_infinite -5/17/2020
290That's where all the fun is! And the $$$MiroSI-1/28/2020
289I guess you are right.Crueldog-1/26/2020
288They all moved to stocktwits… lolyofal-1/21/2020
287what happened to this board. tril has busted loose and conversation ended.Crueldog-1/20/2020
286I think so ;-)yofal-1/2/2020
285FTSV is, without doubt, a better run company. Like LOXO vs BPMC. But there areClarksterh-12/31/2019
284It has had quite a run already. A run that's based upon FTSV data.semi_infinite -12/31/2019
283Does anyone here think TRIL is a buy? BladerunnerBladerunner17-12/30/2019
282If I had bought TRIL a few weeks ago at $.30, as a friend suggested, I would havBladerunner17112/26/2019
281FTSV - CC later today after ASH sessions. ir.fortyseveninc.comsemi_infinite -12/9/2019
280Oddly, Trillium has made no announcement of this licensing deal from yesterday. tuck-9/26/2019
279Stanford - cd47 is not the complete solution. med.stanford.edusemi_infinite -8/1/2019
278Another approach to CD47. nature.comsemi_infinite 17/3/2019
277Wow. I wonder what it could do in earlier interventions, or even if that is waratticus4paws-6/13/2019
276AFMD - AFM13 combo with Pembro continues to impress. onlinelibrary.wiley.comsemi_infinite -6/13/2019
275Tweet regarding Forty-Seven's updated results (which aren't being receivtuck-5/16/2019
274"It will some time and some more dilution before they have much to show anysemi_infinite -4/30/2019
273So Dr. Stiernholm is out, and Dr. Uger takes the helm for the moment. Share prituck-4/30/2019
272Arch gets funding for ph 1 trial. businesswire.comsemi_infinite -3/26/2019
271>>Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPa axis and tuck-3/5/2019
270Good idea to see if all time low at 0.48 holds. IMO it gets tested at the leastsemi_infinite -3/1/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News